share_log

Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

Moderna將於2024年8月1日星期四公佈第二季度財務業績。
Accesswire ·  07/10 07:00

CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update.

馬薩諸塞州劍橋市/ACCESSWIRE/2024年7月10日/Moderna, Inc.(納斯達克股票代碼:MRNA)今天宣佈,它將在美國東部時間2024年8月1日星期四上午8點舉行電話會議和網絡直播,報告其2024年第二季度財務業績,並提供公司最新情況。

A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.

電話會議的網絡直播將在Moderna網站的 “投資者專區” 的 “活動和演講” 下提供。

  • Webcast:

  • 網絡直播:

The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.

存檔的網絡直播將在電話會議結束大約兩小時後在Moderna的網站上播出,並將在電話會議結束後的一年內播出。

About Moderna

關於 Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna 是創建 mRNA 醫學領域的領導者。通過mRNA技術的進步,Moderna正在重新構想藥物的製造方式,並改變我們爲所有人治療和預防疾病的方式。通過在科學、技術和健康的交匯處工作了十多年,該公司以前所未有的速度和效率開發了藥物,包括最早和最有效的 COVID-19 疫苗之一。

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna 的 mRNA 平台使傳染病、免疫腫瘤學、罕見病和自身免疫性疾病的療法和疫苗的開發成爲可能。憑藉獨特的文化和以 Moderna 價值觀和心態爲驅動的全球團隊,負責任地改變人類健康的未來,Moderna 致力於通過 mRNA 藥物爲人們帶來儘可能大的影響。要了解有關 Moderna 的更多信息,請訪問 modernatx.com 並通過 X(前身爲 Twitter)、Facebook、Instagram、YouTube 和 LinkedIn 聯繫我們。

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

投資者:
Lavina Talukdar
高級副總裁兼投資者關係主管
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

資料來源:Moderna, Inc.


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論